Telomere Parameters in Patients With Nonalcoholic Fatty Liver

FATTY LIVER Clinical Trial

— telomereFL  

Official title:

Telomere Parameters Like Telomere Length, Telomerase Expression, Telomere Capture and Aneuploidy in Patients With Nonalcoholic Fatty Liver

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01694342
• Other study ID #: ramona 1.0
• Status: Not yet recruiting
• Phase: N/A
• First received: September 23, 2012
• Last updated: September 26, 2012
• Start date: September 2012

Study information

• Verified date: July 2012
• Source: Meir Medical Center
• Contact: Yona Kitay-Cohen, MD
• Phone: +97297471560
• Email: yonaki[@]clalit.org.il
• Is FDA regulated: No
• Health authority: Israel: Ethics Commission
• Study type: Observational

Clinical Trial Summary

Telomerase, through its regulatory function on telomere length may play an important role in immune function, cellular replicative life span, and carcinogenesis. Non-alcoholic fatty liver disease (NAFLD) is considered a benign condition, but in some cases, it may progress to cirrhosis and hepatocellular carcinoma. The risk factors for that evolution are not fully understood.

Our group showed in a previous study, that hTERT mRNA expression is lower in peripheral lymphocytes of patients with fatty liver, compared to healthy controls. This finding could explain the telomere shortening found previously in these patients by our group [20] and others [21]. Furthermore, we found higher rates of TC in these patients, probably due to an attempt to counteract the shortening of the telomeres and to stabilize them. This is through a different mechanism that is not telomerase-mediated.

Telomere capture is considered an alternative way to maintain telomere length and chromosomal stability [3]. It is a more common mechanism for chromosome stabilization and repair, in contrast to the telomerase-mediated process of chromosome healing and elongation This study aimed to evaluate mechanisms of telomere homeostasis like telomere shortening, telomerase activity, telomere capture and aneuploidy in patients with NAFLD in order to explain previous findings of telomere shortening in these patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• age over 18

• diagnosis of fatty liver

Exclusion Criteria:

• no malignancy

• no eligible to sign the consent paper

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• FATTY LIVER
• NO DECOMPENSATED ILLNESS
• NO MALIGNANCY

Locations

Country	Name	City	State
Israel	Meir Hospital	Kefar Saba

Sponsors (1)

Lead Sponsor	Collaborator
Meir Medical Center

Country where clinical trial is conducted

Israel,